Adseverin: A novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis

Molecular Oncology

Volumn 6, Issue 3, 2012, Pages 311-322

  Miura, Noriyoshi ^a   Takemori, Nobuaki ^a   Kikugawa, Tadahiko ^a   Tanji, Nozomu ^a   Higashiyama, Shigeki ^a   Yokoyama, Masayoshi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adseverin; Cisplatin; Drug resistant; Proteomics; Urothelial carcinoma

Indexed keywords

ACTIN BINDING PROTEIN; ADSEVERIN; CISPLATIN; MESSENGER RNA; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; FRACTIONATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

EID: 84861459343     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.12.002     Document Type: Article

References (39)

1. Abu-Hamad S., Arbel N., Calo D., Arzoine L., Israelson A., Keinan N., Ben-Romano R., Friedman O., Shoshan-Barmatz V. The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. J. Cell Sci. 2009, 122:1906-1916.
2. American Cancer Society Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta.
3. Arbel N., Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. J. Biol. Chem. 2010, 285:6053-6062.
4. Arzoine L., Zilberberg N., Ben-Romano R., Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J. Biol. Chem. 2009, 284:3946-3955.
5. Azoulay-Zohar H., Israelson A., Abu-Hamad S., Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem. J. 2004, 377:347-355.
6. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., Zunino F., Righetti P.G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
7. Chumnarnsilpa S., Lee W.L., Nag S., Kannan B., Larsson M., Burtnick L.D., Robinson R.C. The crystal structure of the C-terminus of adseverin reveals the actin-binding interface. PNAS 2009, 106:13719-13724.
8. Dai Z., Yin J., He H., Li W., Hou C., Qian X., Mao N., Pan L. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 2010, 10:3789-3799.
9. De Pinto V., Tomasello F., Messina A., Guarino F., Benz R., La Mendola D., Magrì A., Milardi D., Pappalardo G. Determination of the conformation of the human VDAC1 N-terminal peptide, a protein moiety essential for the functional properties of the pore. Chembiochem 2007, 8:744-756.
10. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988, 27:4730-4734.
11. Fukumori T., Oka N., Takenaka Y., Nangia-Makker P., Elsamman E., Kasai T., Shono M., Kanayama H.O., Ellerhorst J., Lotan R., Raz A. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 2006, 66:3114-3119.
12. Fukumori T., Kanayama H., Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist. Updates 2007, 10:101-108.
13. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 2001, 59:657-663.
14. Hodgkinson V.C., Eagle G.L., Drew P.J., Lind M.J., Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett. 2010, 294:13-24.
15. Hour T.C., Lai Y.L., Kuan C.I., Chou C.K., Wang J.M., Tu H.Y., Hu H.T., Lin C.S., Wu W.J., Pu Y.S., Sterneck E., Huang A.M. Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells. Biochem. Pharmacol. 2010, 80:325-334.
16. Keinan N., Tyomkin D., Shoshan-Barmatz V. Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol. Cell Biol. 2010, 30:5698-5709.
17. Kusano H., Shimizu S., Koya R.C., Fujita H., Kamada S., Kuzumaki N., Tsujimoto Y. Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 2000, 19:4807-4814.
18. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the " Warburg effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 2009, 19:17-24.
19. Picotti P., Rinner O., Stallmach R., Dautel F., Farrah T., Domon B., Wenschuh H., Aebersold R. High-high-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 2010, 7:43-46.
20. Plebuch M., Soldan M., Hungerer C., Koch L., Maser E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 2007, 255:49-56.
21. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
22. Rappsilber J., Ishihama Y., Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 2003, 75:663-670.
23. Richon V.M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987, 47:2056-2061.
24. Roberts J.T., von der Maase H., Sengeløv L., Conte P.F., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann. Oncol. 2006, (Suppl. 5):v118-v122.
25. Schmitz-Spanke S., Rettenmeier A.W. Protein expression profiling in chemical carcinogenesis: a proteomic-based approach. Proteomics 2011, 11:644-656.
26. Shi Y., Chen J., Weng C., Chen R., Zheng Y., Chen Q., Tang H. Identification of the protein-protein contact site and interaction mode of human VDAC1 with Bcl-2 family proteins. Biochem. Biophys. Res. Commun. 2003, 305:989-996.
27. Shoshan-Barmatz V., Keinan N., Abu-Hamad S., Tyomkin D., Aram L. Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo. Biochim. Biophys. Acta 2010, 1797:1281-1291.
28. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
29. Sun Q.L., Sha H.F., Yang X.H., Bao G.L., Lu J., Xie Y.Y. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J. Cancer Res. Clin. Oncol. 2011, 137:521-532.
30. Tajeddine N., Galluzzi L., Kepp O., Hangen E., Morselli E., Senovilla L., Araujo N., Pinna G., Larochette N., Zamzami N., Modjtahedi N., Harel-Bellan A., Kroemer G. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27:4221-4232.
31. Takemori N., Yamamoto M.T. Proteome mapping of the Drosophila melanogaster male reproductive system. Proteomics 2009, 9:2484-2493.
32. Tanji N., Ozawa A., Miura N., Yanagihara Y., Sasaki T., Nishida T., Kikugawa T., Ikeda T., Ochi T., Shimamoto K., Aoki K., Yokoyama M. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int. J. Clin. Oncol. 2010, 15:369-375.
33. Teicher B.A., Holden S.A., Kelley M.J., Shea T.C., Cucchi C.A., Rosowsky A., Henner W.D., Frei E. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987, 47:388-393.
34. Tsujimoto Y., Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 2000, 7:1174-1181.
35. Tsunoda T., Koga H., Yokomizo A., Tatsugami K., Eto M., Inokuchi J., Hirata A., Masuda K., Okumura K., Naito S. Inositol 1,4,5-trisphosphate (IP 3) receptor type1 (IP 3 R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 2005, 24:1396-1402.
36. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000, 18:3068-3077.
37. Wessel D., Flügge U.I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 1984, 138:141-143.
38. Zalk R., Israelson A., Garty E.S., Azoulay-Zohar H., Shoshan-Barmatz V. Oligomeric states of the voltage-dependent anion channel and cytochrome c release from mitochondria. Biochem. J. 2005, 386:73-83.
39. Zheng G., Peng F., Ding R., Yu Y., Ouyang Y., Chen Z., Xiao Z., He Z. Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. J. Cancer Res. Clin. Oncol. 2010, 136:1477-1488.